R
Revelation Biosciences, Inc. (REVB)
NCM – Real vaqt narxi. Valyuta: USD
1.04
+0.06 (6.31%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
1.04
+0.06 (6.31%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Revelation Biosciences, Inc. sog'lomlikni optimallashtirish uchun yallig'lanish muvozanatini tiklashga qaratilgan klinik bosqichdagi hayotiy fanlar kompaniyasi sifatida faoliyat yuritadi. Kompaniyaning asosiy mahsulot nomzodi fosforlangan geksaatsil disaharidining (PHAD) patentlangan formulasi platformasi bo'lgan asosiy mahsulot nomzodi Gemini hisoblanadi. Bu Toll-like retseptor 4 (TLR) agonisti bo'lib, u tartibsiz yallig'lanish javobini modulyatsiya qilish va muvozanatlash orqali ishlaydi. Shuningdek, u tug'ma immunitet tizimini modulyatsiya qiluvchi terapevtik vositalarni ishlab chiqish va tijoratlashtirish orqali kasalliklarning oldini olish va davolash bilan shug'ullanadi, shu jumladan buyrak shikastlanishining oldini olish va davolash uchun potentsial terapiya GEM-AKI; va surunkali buyrak kasalliklarining oldini olish va davolash uchun potentsial terapiya GEM-CKD. Kompaniya ilgari Petra Acquisition, Inc. nomi bilan tanilgan va 2022-yil yanvar oyida Revelation Biosciences, Inc. nomini olgan. Revelation Biosciences, Inc. 2019-yilda tashkil etilgan va San-Diegoda, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Mr. Chester Stanley Zygmont III | CFO & Corporate Secretary |
| Mr. James M. Rolke | Chairman & CEO |
| Ms. Carol Odle | Senior Director of Clinical Projects |
| Ms. Sandra Vedrick | Vice President of Human Resources & Investor Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | revb-20260507.htm |
| 2026-04-15 | S-8 | revb-20260415.htm |
| 2026-03-19 | 8-K | revb-20260318.htm |
| 2026-02-26 | 8-K | revb-20251106.htm |
| 2026-02-26 | 10-K | revb-20251231.htm |
| 2026-02-17 | DEF 14A | revb-20260214.htm |
| 2026-02-09 | CORRESP | filename1.htm |
| 2026-01-30 | S-3 | revb-20260130.htm |
| 2026-01-29 | 8-K | revb-20260126.htm |
| 2026-01-22 | 8-K | revb-20260121.htm |